Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study
Cancer Medicine · 2023
DOI: 10.1002/cam4.6470 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2023. Verfasst von Toshihiko Masui und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Radiotherapy, Intensity-Modulated, Chemoradiotherapy, Adjuvant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Resectable pancreatic cancer (RPC) is potentially resectable on admission, and the impact of neoadjuvant therapy on these tumors is controversial. Moreover, the safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiation therapy (NACIMRT) for RPC have not been studied. Here, we conducted a phase II study to evaluate the safety and efficacy of hypofractionated NACIMRT for RPC.
Methods
A total of 54 RPC patients were enrolled and treated according to the study protocol. We used moderately hypofractionated (45 Gy in 15 fractions) IMRT with gemcitabine to shorten the duration of radiotherapy and reduce gastrointestinal toxicity. The primary endpoint was overall survival (OS), and we subsequently analyzed the microscopically margin‐negative resection (R0) rate, disease‐free survival (DFS), and histologic effects and safety of NACIMRT.
Results
Median OS for the cohort was 40.0 months. Forty‐two patients (77.8%) underwent pancreatectomy after NACIMRT. Median DFS was 20.3 months. The R0 resection rate was 95.2% (40/42) per protocol and 85.2% (46/54) for the cohort. There were no intervention‐related deaths during the study period. Local treatment response, as assessed by the CAP classification, showed no residual tumor in 4.8% of patients. Overall, 23.9% of patients experienced CTCAE grade 3 or 4 during NACIMRT. Adjuvant therapy was initiated in 88% of patients undergoing resection. Postoperative complications grade ≥3b on the Clavien–Dindo scale occurred in 4.8% of patients. CA19‐9 level at enrollment was an independent prognostic factor for OS and DFS.
Conclusions
This is the first prospective study of hypofractionated IMRT as neoadjuvant therapy for RPC. Hypofractionated NACIMRT for RPC could be safely introduced with a high induction rate of adjuvant chemotherapy, with an overall survival of 40.0 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Kyoto University, Kyoto, Japan.
- Department of Real World Data Research and Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Clinical Oncology, Kyoto University, Kyoto, Japan.
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Toshihiko Masui, Takashi Mizowaki, Masashi Kanai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Masui, T., Nagai, K., Anazawa, T., Kasai, Y., Yogo, A., Yoshimura, M., Mizowaki, T., Uza, N., Fukuda, A., Matsumoto, S., Kanai, M., Isoda, H., Kawaguchi, Y., Uemoto, S., & Hatano, E. (2023). Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study. Cancer Medicine. https://doi.org/10.1002/cam4.6470
Vancouver
Masui T, Nagai K, Anazawa T, Kasai Y, Yogo A, Yoshimura M, et al. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study. Cancer Medicine. 2023. doi:10.1002/cam4.6470
BibTeX
@article{Masui2023,
author = {Masui, Toshihiko and Nagai, Kazuyuki and Anazawa, Takayuki and Kasai, Yosuke and Yogo, Akitada and Yoshimura, Michio and Mizowaki, Takashi and Uza, Norimitsu and Fukuda, Akihisa and Matsumoto, Shigemi and Kanai, Masashi and Isoda, Hiroyoshi and Kawaguchi, Yoshiya and Uemoto, Shinji and Hatano, Etsuro},
title = {Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6470}
}
EUVIMED